ANHYDROUS CRYSTALLINE FORM OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME

Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-t...

Full description

Saved in:
Bibliographic Details
Main Authors RORTAIS, Patricia, ZASKE, Lionel, GUILIANI, Alexandre, BILLOT, Pascal, ELMALEH, Hagit, DUFRAIGNE, Marielle, MANGIN, Fabrice
Format Patent
LanguageEnglish
Lithuanian
Published 25.01.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) are new. Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C, dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) are new, where: the anhydrous forms B-F are characterized by a X-ray diffraction powder (XRDP) having peaks at 7.3, 8.1, 9.8, 10.4, 11.1, 12.7, 13.1, 14.3, 15.4 and 15.9 +- 0.2[deg] 2theta , 4.3, 6.8, 7.4, 8.7, 10.1, 11.1, 11.9, 12.3, 12.6 and 13.1 +- 0.2[deg] 2theta , 3.9, 7.7, 7.8, 7.9, 8.6, 9.7, 10.6, 10.8, 11.1 and 12.3 +- 0.2[deg] 2theta , 7.1, 8.1, 8.9, 10.2, 10.8, 12.5, 12.7, 13.2, 13.4 and 13.9 +- 0.2[deg] 2theta and 4.4, 7.2, 8.2, 8.8, 9.6, 10.2, 10.9, 11.2, 12.1 and 12.3 +- 0.2[deg] 2theta , respectively; the ethanolate forms B, D and E are characterized by a XRDP having peaks at 7.3, 7.8, 8.8, 10.2, 12.6, 12.9, 13.4, 14.2, 14.7 et 15.1 +- 0.2[deg] 2theta , 3.8, 7.5, 7.7, 8.4, 9.4, 10.3, 10.5, 11.1, 11.5 and 11.9 +- 0.2[deg] 2theta and 7.1, 8.1, 8.8, 10.2, 10.7, 12.5, 13.2, 13.4, 13.9 and 14.2 +- 0.2[deg] 2theta , respectively; the hetero-solvate form F is characterized by XRDP having peaks at 4.4, 7.2, 8.2, 8.3, 8.8, 9.6, 10.3, 10.9, 11.2 and 12.2 +- 0.2[deg] 2theta ; the monohydrate form C is characterized by XRDP having peaks at 4.3, 6.8, 7.4, 8.6, 10.1, 11.1, 11.9, 12.2, 12.6 and 13.3 +- 0.2[deg] 2theta ; and the dihydrate form C is characterized by XRDP having peaks at 4.2, 6.9, 7.5, 8.4, 9.9, 10.9, 11.7, 12.3, 12.6 and 13.2 +- 0.2[deg] 2theta . Independent claims are included for the preparations of anhydrous forms B-F of (I). ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.
AbstractList Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) are new. Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C, dihydrate form C of 4-acetoxy-2alpha -benzoyloxy-5beta ,20-epoxy-1-hydroxy-7beta ,10beta -dimethoxy-9-oxo-tax-11-ene-13alpha -yl-(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I) are new, where: the anhydrous forms B-F are characterized by a X-ray diffraction powder (XRDP) having peaks at 7.3, 8.1, 9.8, 10.4, 11.1, 12.7, 13.1, 14.3, 15.4 and 15.9 +- 0.2[deg] 2theta , 4.3, 6.8, 7.4, 8.7, 10.1, 11.1, 11.9, 12.3, 12.6 and 13.1 +- 0.2[deg] 2theta , 3.9, 7.7, 7.8, 7.9, 8.6, 9.7, 10.6, 10.8, 11.1 and 12.3 +- 0.2[deg] 2theta , 7.1, 8.1, 8.9, 10.2, 10.8, 12.5, 12.7, 13.2, 13.4 and 13.9 +- 0.2[deg] 2theta and 4.4, 7.2, 8.2, 8.8, 9.6, 10.2, 10.9, 11.2, 12.1 and 12.3 +- 0.2[deg] 2theta , respectively; the ethanolate forms B, D and E are characterized by a XRDP having peaks at 7.3, 7.8, 8.8, 10.2, 12.6, 12.9, 13.4, 14.2, 14.7 et 15.1 +- 0.2[deg] 2theta , 3.8, 7.5, 7.7, 8.4, 9.4, 10.3, 10.5, 11.1, 11.5 and 11.9 +- 0.2[deg] 2theta and 7.1, 8.1, 8.8, 10.2, 10.7, 12.5, 13.2, 13.4, 13.9 and 14.2 +- 0.2[deg] 2theta , respectively; the hetero-solvate form F is characterized by XRDP having peaks at 4.4, 7.2, 8.2, 8.3, 8.8, 9.6, 10.3, 10.9, 11.2 and 12.2 +- 0.2[deg] 2theta ; the monohydrate form C is characterized by XRDP having peaks at 4.3, 6.8, 7.4, 8.6, 10.1, 11.1, 11.9, 12.2, 12.6 and 13.3 +- 0.2[deg] 2theta ; and the dihydrate form C is characterized by XRDP having peaks at 4.2, 6.9, 7.5, 8.4, 9.9, 10.9, 11.7, 12.3, 12.6 and 13.2 +- 0.2[deg] 2theta . Independent claims are included for the preparations of anhydrous forms B-F of (I). ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.
Author ELMALEH, Hagit
GUILIANI, Alexandre
ZASKE, Lionel
DUFRAIGNE, Marielle
BILLOT, Pascal
MANGIN, Fabrice
RORTAIS, Patricia
Author_xml – fullname: RORTAIS, Patricia
– fullname: ZASKE, Lionel
– fullname: GUILIANI, Alexandre
– fullname: BILLOT, Pascal
– fullname: ELMALEH, Hagit
– fullname: DUFRAIGNE, Marielle
– fullname: MANGIN, Fabrice
BookMark eNqNyksKwjAQgOEsdOHrDnMBN1HR7dBMbCCPkozQrkqRuJK0UO-PKB7A1Q8_31osyljySjTo607FcEtQxS4xWms8gQ7RQdCgjCOuQ9uBChUxtmQBvYLvVenjoInUYDT-CgkdbcXyMTznvPt1I0ATV_U-T2Of52m455JfvWUpj-fTRTIf_iBvcVcxGw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate DIMETOKSIDOCETAKSELIO BEVANDENĖ KRISTALINĖ FORMA
ExternalDocumentID LT2247582TT
GroupedDBID EVB
ID FETCH-epo_espacenet_LT2247582TT3
IEDL.DBID EVB
IngestDate Fri Jul 19 14:53:20 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
Lithuanian
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_LT2247582TT3
Notes Application Number: LT09722321T
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170125&DB=EPODOC&CC=LT&NR=2247582T
ParticipantIDs epo_espacenet_LT2247582TT
PublicationCentury 2000
PublicationDate 20170125
PublicationDateYYYYMMDD 2017-01-25
PublicationDate_xml – month: 01
  year: 2017
  text: 20170125
  day: 25
PublicationDecade 2010
PublicationYear 2017
RelatedCompanies Aventis Pharma S.A
RelatedCompanies_xml – name: Aventis Pharma S.A
Score 3.070561
Snippet Anhydrous forms B-F, ethanolic solvate/heterosolvate forms, preferably ethanolate forms B, D and E, heterosolvate form F, hydrate forms, monohydrate form C and...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Title ANHYDROUS CRYSTALLINE FORM OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170125&DB=EPODOC&locale=&CC=LT&NR=2247582T
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8gGvVNUQN-pQ9mb0Q2NgYPixlrl2nYR7ZixhMpDKKJASIz_vteG6a-6Fu_crlecr37Xa9XgDsxsIRuCMQmhm20TX3ZaeMZuJRlXDsD0bX7uop3hFEvGJtPuZXX4KV6C6PqhH6q4oioUXPU91Kd15ufIBZVuZXb-9krDq0ffO5QbYeOZXFxw9Lo0GFJTGNP8zxnxLUoddBSoWds8D3YRyfalrrAnofyTcrmt0HxT-AgQVqr8hRqb2UDjrzq37UGHIa7625s7jRvewaJGwUTmsbjjHjpJOMugvCIEcRwIYl9Qh9DxoM4nxDkh3E3ZyPiRpSoUZrJdQSFnbgy-YFkbsjOgfiMe0EbWZt-S2E64tUeePcC6qv1atEEMrcLoXet3qzXL0x0bcRSIC7ErijMOfpCLWj9Sebyn7krOJbilMEGw7qGevn-sbhB81vObpXkvgAOGYLU
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLbGQIwbDBDjmQPqbWJ9rduhQl2TqkBfWjPUnabsJZDQNrEi_j5OtAEXuOUlK7bk2J_jOAC3omsL3RCITQzHaFr6vNXEM3Auy7i2usJ0OrqKd8RJOxxYj4VdVOBl-xZG1Qn9VMURUaMmqO-lOq9XP0EsqnIr13fjVxxa3gfcpdoGHcvi4oat0Z7LspSmvub7bsS1pO-ipULP2OA7sIsOtiN1gT335JuU1W-DEhzCXoa0FuURVN7KOtT87b9rddiPN9fd2Nxo3voYMi8Jh7SfDnLi94c59xCEJ4wghotJGhD6EDMepsWQ4H4Y9woWES-hRI3SXK4jKOzMk8kPJPdidgIkYNwPm7i10bcURhHf8sDNU6gulovZGZCJMxW6abfH7c7UQtdGzAXiQuyKqTVBX6gBjT_JnP8zdwO1kMfRCHl5uoADKVoZeDDsS6iW7x-zKzTF5fhaSfELXOOFxw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANHYDROUS+CRYSTALLINE+FORM+OF+DIMETHOXY+DOCETAXEL+AND+METHODS+FOR+PREPARING+SAME&rft.inventor=RORTAIS%2C+Patricia&rft.inventor=ZASKE%2C+Lionel&rft.inventor=GUILIANI%2C+Alexandre&rft.inventor=BILLOT%2C+Pascal&rft.inventor=ELMALEH%2C+Hagit&rft.inventor=DUFRAIGNE%2C+Marielle&rft.inventor=MANGIN%2C+Fabrice&rft.date=2017-01-25&rft.externalDBID=T&rft.externalDocID=LT2247582TT